Mode
Text Size
Log in / Sign up
N/A N=96 Randomized Quadruple-blind Treatment

Altering Activation Patterns Post-stroke

Stroke · Muscle Spasticity · Hemiparesis

Enrolled (actual)
96
Serious AEs
5.2%
Results posted
Jul 2021
Primary outcome: Primary: Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) — -3.66; -0.51; -4.00; -3.89 Seconds

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cyproheptadine (Drug); Placebo for Cyproheptadine (Drug); Active Movement Practice (AMP) (Other); Passive Cyclical Stretching (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Shirley Ryan AbilityLab
Primary completion
Aug 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT)
-3.66; -0.51; -4.00; -3.89
SECONDARY
Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC)
-1.66; -0.96; -1.06; -2.65

Summary

This study evaluates a new rehabilitation approach for stroke survivors in the chronic phase of recovery in which the combination of drug therapy (cyproheptadine) and active movement practice (AMP) is used to encourage increased voluntary muscle control and strength.

Eligibility Criteria

Inclusion Criteria

  • Chronic, severe hand hemiparesis resulting from a single stroke (Chedoke- McMaster Stroke Assessment: Stage of Hand 2 or 3)
  • Single stroke occurring at least 6 months prior to enrollment
  • Spasticity
  • Capacity to provide informed consent

Exclusion Criteria

  • Excessive pain in paretic upper limb
  • Hemispatial neglect (as assessed by the Behavioral Inattention Test)
  • Apraxia (as assessed by the FABERS battery)
  • Botulinum toxin injection in the upper extremity within the past 6 months
  • Introduction of new anti-spasticity medication within the past 6 months
  • Orthopaedic impairments
  • History of seizure disorder
  • Other major health impairment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02418949). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search